51 completed, 35 recruiting, 26 active not recruiting, 23 terminated. 114 Phase 2, 76 Phase 1, 19 Phase 3, 5 Not applicable, 1 Early Phase 1.
Follow selinexor: new trials by email Literature Review of selinexor trials Research Report on selinexor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial Imlunestrant, Abemaciclib, Selinexor - Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 60 | 2026-12-01 | 2026-09-21 |
| The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations Selinexor - Myeloid Tumors | Not applicable | Not yet recruiting | Bing Han | 30 | 2026-11-01 | 2026-06-08 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Recruiting | John Mascarenhas | 26 | 2026-10-23 | 2026-10-27 |
| New Genotype-guided Treatment in Newly Diagnosed PTCL Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP - Peripheral T-cell Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 108 | 2026-07-01 | 2026-07-16 |
| Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms Selinexor - Myeloproliferative Neoplasms | Phase 2 | Not yet recruiting | Zhongshan Hospital (Xiamen), Fudan University | 15 | 2026-07-01 | 2026-06-04 |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection) - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 255 | 2026-06-11 | 2026-09-17 |
| Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Glofitamab combined with selinexor - Diffuse Large B-Cell Lymphoma (DLBCL) | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 30 | 2026-06-10 | 2026-06-25 | |
| Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma TQB2934 injection, Pomalidomide Capsule, Selinexor tablets - Multiple Myeloma | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 260 | 2026-06-01 | 2026-05-08 |
| Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Natalie Callander | 62 | 2026-05-21 | 2026-08-31 |
| Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma Pegaspargase (PEG) Asparaginase, Gemcitabine (GEM), Oxaliplatin - Extranodal NK/T-cell Lymphoma | Phase 2 | Not yet recruiting | Beijing Tongren Hospital | 34 | 2026-05-15 | 2026-04-28 |
| A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma Sintilimab, Pegaspargase, Selinexor - NKTCL | Phase 2 | Not yet recruiting | Sun Yat-sen University | 47 | 2026-05-06 | 2026-05-08 |
| Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma Selinexor - Multiple Myeloma | Phase 1 | Recruiting | Washington University School of Medicine | 20 | 2026-03-17 | 2026-10-15 |
| A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 261 | 2026-01-25 | 2026-05-12 |
| Golidocitinib Combined With Selinexor for CAEBVD golidocitinib, Selinexor (combination therapy) - Lymphohistiocytosis, EBV | Phase 2 / Phase 3 | Recruiting | Beijing Friendship Hospital | 28 | 2026-01-01 | 2026-01-27 |
| Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma Selinexor, azacitidine - NK T-Cell Lymphoma | Phase 2 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 39 | 2025-12-30 | 2025-12-11 |
| A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma QLS32015, Pomalidomide, Selinexor - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 228 | 2025-11-07 | 2026-05-22 |
| Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer Selinexor, Anlotinib, DLL3 CAR-NK cells - Extensive Stage Lung Small Cell Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 165 | 2025-11-01 | 2025-09-30 |
| HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM Selinexor 40 mg - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 2 | Recruiting | Duke University | 27 | 2025-08-22 | 2026-09-03 |
| Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH Selinexor, Thalidomide (100mg), Dexamethasone - Langerhans Cell Histiocytosis (LCH) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2025-08-01 | 2025-10-02 |
| A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma Purinostat Mesylate for Injection, Selinexor Tablets - Recurrent and Refractory Diffuse Large B-cell Lymphoma | Phase 3 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 390 | 2025-07-18 | 2025-09-19 |
Showing 20 of 183. Sign in to see all of them.
Multiple Myeloma (48) · Leukemia, Myeloid, Acute (26) · Recurrence (26) · Lymphoma, Large B-Cell, Diffuse (14) · Sarcoma (9) · Endometrial Neoplasms (6) · Lymphoma (6) · Primary Myelofibrosis (6) · Glioblastoma (5) · Lymphoma, T-Cell, Peripheral (5) · Myelodysplastic Syndromes (5) · Neoplasm Metastasis (5) · Neoplasms, Plasma Cell (5) · Ovarian Neoplasms (5) · Colorectal Neoplasms (4)
Karyopharm Therapeutics Inc (34) · H. Lee Moffitt Cancer Center and Research Institute (6) · National Cancer Institute (NCI) (5) · Ruijin Hospital (5) · St. Jude Children's Research Hospital (5) · Institute of Hematology & Blood Diseases Hospital, China (4) · Memorial Sloan Kettering Cancer Center (4) · University Health Network, Toronto (4) · Antengene Corporation (3) · National University Hospital, Singapore (3) · Sun Yat-sen University (3) · The First Affiliated Hospital of Soochow University (3) · University of Chicago (3) · Washington University School of Medicine (3) · Weill Medical College of Cornell University (3)
United States (90) · China (52) · Canada (21) · Spain (19) · Germany (16) · Israel (14) · France (13) · Belgium (12) · Greece (11) · Italy (11) · Denmark (10) · United Kingdom (10) · Poland (9) · Australia (8) · Austria (6)
Albiruni Razak, M.D. (2) · Erin Bertino, MD (2) · Hongtao Liu (2) · Jeffrey E. Rubnitz, MD,PhD (2) · A P Chen (1) · Abdulraheem Yacoub, MD (1) · Adam L Green (1) · Alice Mims, MD (1) · Amar Gajjar, MD (1) · Amit Mahipal, M.D. (1) · Andrew B Lassman, MD (1) · Andrew E Place, MD,PhD (1) · Andrzej Jakubowiak (1) · Anna Spreafico (1)
PMID 27507877, PMID 31433920, PMID 32589977, PMID 37393120, PMID 38826786, PMID 16648042, PMID 19219604, PMID 20660832, PMID 23615461, PMID 23752175, PMID 23753028, PMID 23927993, PMID 24743138, PMID 25934708, PMID 27458288, PMID 27557643, PMID 28148715, PMID 28188133, PMID 28336527, PMID 28468797, PMID 28630120, PMID 29155058, PMID 29203585, PMID 29304833, PMID 29381435, PMID 29437609, PMID 29487219, PMID 29610030, PMID 29654631, PMID 29773601, PMID 30345906, PMID 30352784, PMID 30610226, PMID 30689707, PMID 30881137, PMID 30996012, PMID 31124580, PMID 31545113, PMID 31822399, PMID 31831564, PMID 32487143, PMID 32598257, PMID 32735836, PMID 33023948, PMID 33148342, PMID 33189178, PMID 33202794, PMID 33528286, PMID 33755235, PMID 33764240
2017 (3), P30CA014599 (3), 2014 (2), 2023 (2), 2015 (1), 2019 (1), P01CA108671 (1), P30CA012197 (1), P30CA015083 (1), P30CA022453 (1), P30CA046934 (1), P30CA093373 (1), P50CA097274 (1), P50CA100632 (1), U10CA180886 (1)